



Humira and Biosimilars Order Form

Please fax all pages of completed form to our Intake team at 888.276.7948

Contact our Intake team 800.422.5059 ext. 1480

1

Patient Information — Please provide copies of front and back of all medical and prescription insurance cards.

☐ New patient ☐ Current patient

Patient's first name _____ Last name _____ MI _____

Preferred patient first name _____ Preferred patient last name _____

Sex at birth: ☐ Male ☐ Female Gender identity _____ Pronouns _____

Last 4 of SSN _____ Date of birth ____/____/____

Street address _____ Apt # _____

City _____ State _____ Zip _____

Home phone _____ Cell phone _____ Email address _____

Parent/guardian (if applicable)

Home phone _____ Cell phone _____ Email address _____

Alternate caregiver/contact

Home phone _____ Cell phone _____ Email address _____

☐ OK to leave message with alternate caregiver/contact

Patient's primary language: ☐ English ☐ Other If other, please specify _____

Provider will read the following statement to patient: By providing the phone number(s) and email address above, you consent to receiving automated/artificial voice calls, emails and/or text messages from Barnes Healthcare Services about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies.

2

Prescriber Information — All fields must be completed to expedite prescription fulfillment.

Date _____ Time _____ Date medication needed ____/____/____

Office/clinic/institution name

Prescriber's first name _____ Last name _____

Prescriber's title _____ If NP or PA, under direction of Dr. _____

Office phone _____ Fax _____ NPI # _____ License # _____

Office contact and title _____ Office contact email _____

Office street address _____ Suite # _____

City _____ State _____ Zip _____

Infusion location: ☐ Patient's home ☐ Prescriber's office ☐ Infusion site

If infusion site, complete information below:

Infusion site name _____ Clinic/hospital affiliation _____

Site street address _____ Suite # _____

City _____ State _____ Zip _____

Infusion site contact _____ Phone _____ Fax _____

Email _____

Note: Check the appropriate shipment options in Section 4: Prescribing Information.

3 Clinical Information

Primary ICD-10 code (REQUIRED): _____

 Has the patient been treated previously for this condition? ☐ Yes ☐ No

 Is patient currently on therapy? ☐ Yes ☐ No

Please list all therapies tried/failed: _____

Patient wt _____ Date wt obtained: ____/____/____

☐ NKDA Known drug allergies _____

Concurrent meds: _____

4 Prescribing Information

Patient weight is requested/required for pediatric patients: _____ kg

Medication	Strength / Formulation	Directions	Quantity / Refills
adalimumab-aacf Citrate Free (pediatric weight _____ kg)			
adalimumab-aacf (Citrate Free)	40mg/0.8mL PEN	For Adults and Children ≥6 yrs weighing ≥40kg (88 lbs): Loading dose: ☐ Inject 160mg on day 1 — OR — ☐ Inject 80mg on day 1 and day 2 followed by 80mg SC 2 weeks later (day 15), then maintenance dose starting on day 29	QS for 1-month loading dose No Refills
adalimumab-aacf (Citrate Free)	40mg/0.8mL PEN	For Adults and Children ≥6 yrs weighing ≥40kg: Maintenance dose: Inject 40mg subcutaneously every other week	☐ 1-month supply ☐ 3-month supply ☐ Refill QS 1 year unless otherwise noted ☐ Other _____
Amjevita™ (adalimumab-atto) — Citrate Free — ADULT			
Amjevita™ (ADULT)	☐ 40mg/0.4mL prefilled syringe (PFS) ☐ 40mg/0.4mL SureClick Autoinjector	Loading dose: ☐ Inject 160mg on day 1 — OR — ☐ Inject 80mg on day 1 and day 2 followed by 80mg SC 2 weeks later (day 15), then maintenance dose starting on day 29	QS for 1-month loading dose No Refills
Amjevita™ (ADULT)	☐ 40mg/0.4mL PFS ☐ 40mg/0.4mL SureClick Autoinjector	Maintenance dose: Inject 40mg subcutaneously every other week	☐ 1-month supply ☐ 3-month supply ☐ Refill QS 1 year unless otherwise noted ☐ Other _____

Medication	Strength / Formulation	Directions	Quantity / Refills
Amjevita™ (adalimumab-atto) — Citrate Free — PEDIATRIC (weight _____ kg)			
Amjevita™ (PEDIATRIC)	☐ 40mg/0.4mL PFS ☐ 40mg/0.4mL SureClick Autoinjector	Loading dose: For 17kg to <40kg: ☐ Inject 80mg SC on day 1, then 40mg on day 15, then maintenance on day 29 For ≥40kg: ☐ Inject 160mg day 1 — OR — ☐ Inject 80mg each day 1 and day 2 followed by 80mg SC on day 15, then maintenance on day 29	QS for 1-month loading dose No Refills
Amjevita™ (PEDIATRIC)	☐ 20mg/0.2mL PFS ☐ 40mg/0.4mL PFS ☐ 40mg/0.4mL SureClick Autoinjector	Maintenance dose: For 17kg to <40kg: Inject 20mg SC every other week For ≥40kg: Inject 40mg SC every other week	☐ 1-month supply ☐ 3-month supply ☐ Refill QS 1 year unless otherwise noted ☐ Other _____
Cyltezo® (adalimumab-adbm) — Citrate Free — ADULT			
Cyltezo® (ADULT)	☐ 40mg/0.8mL PEN ☐ 40mg/0.8mL PFS	Loading dose: ☐ Inject 160mg on day 1 — OR — ☐ Inject 80mg on day 1 and day 2 followed by 80mg SC 2 weeks later (day 15), then maintenance on day 29	QS for 1-month loading dose No Refills
Cyltezo® (ADULT)	☐ 40mg/0.8mL PEN ☐ 40mg/0.8mL PFS	Maintenance dose: Inject 40mg subcutaneously every other week	☐ 1-month supply ☐ 3-month supply ☐ Refill QS 1 year unless otherwise noted ☐ Other _____
Cyltezo® (adalimumab-adbm) — Citrate Free — PEDIATRIC (weight _____ kg)			
Cyltezo® (PEDIATRIC)	☐ 40mg/0.8mL PEN ☐ 40mg/0.8mL PFS	Loading dose: For 17kg to <40kg: ☐ Inject 80mg SC on day 1, then 40mg on day 15, then maintenance on day 29 For ≥40kg: ☐ Inject 160mg day 1 — OR — ☐ Inject 80mg on day 1 and day 2 followed by 80mg SC on day 15, then maintenance on day 29	1 starter kit -OR- QS for 1-month loading dose No Refills
Cyltezo® (PEDIATRIC)	☐ 20mg/0.4mL PFS ☐ 40mg/0.8mL PEN ☐ 40mg/0.8mL PFS	Maintenance dose: For 17kg to <40kg: Inject 20mg SC every other week	☐ 1-month supply ☐ 3-month supply

Humira and Biosimilars Order Form

Medication	Strength / Formulation	Directions	Quantity / Refills
		For ≥40kg: Inject 40mg SC every other week	☐ Refill QS 1 year unless otherwise noted ☐ Other _____
adalimumab-adbm — Citrate Free — ADULT			
adalimumab-adbm (ADULT)	☐ 40mg/0.8mL PEN ☐ 40mg/0.8mL PFS	Loading dose: ☐ Inject 160mg on day 1 — OR — ☐ Inject 80mg on day 1 and day 2 followed by 80mg SC on day 15, then maintenance on day 29	QS for 1-month loading dose No Refills
adalimumab-adbm (ADULT)	☐ 40mg/0.8mL PEN ☐ 40mg/0.8mL PFS	Maintenance dose: Inject 40mg subcutaneously every other week	☐ 1-month supply ☐ 3-month supply ☐ Refill QS 1 year unless otherwise noted ☐ Other _____
Hadlima™ (adalimumab-bwwd) — Citrate Free — ADULT			
Hadlima™ (ADULT)	☐ 40mg/0.8mL PFS ☐ 40mg/0.4mL PFS ☐ 40mg/0.8mL PushTouch Autoinjector ☐ 40mg/0.4mL PushTouch Autoinjector	Loading dose: ☐ Inject 160mg on day 1 — OR — ☐ Inject 80mg on day 1 and day 2 followed by 80mg SC on day 15, then maintenance on day 29	QS for 1-month loading dose No Refills
Hadlima™ (ADULT)	☐ 40mg/0.8mL PFS ☐ 40mg/0.4mL PFS ☐ 40mg/0.8mL PushTouch Autoinjector ☐ 40mg/0.4mL PushTouch Autoinjector	Maintenance dose: Inject 40mg subcutaneously every other week	☐ 1-month supply ☐ 3-month supply ☐ Refill QS 1 year unless otherwise noted ☐ Other _____
Humira® (adalimumab) — ADULT			
Humira® (ADULT)	Starter: ☐ 80mg/0.8mL prefilled PEN Starter Package (3 PENS) ☐ 40mg/0.4mL PFS for starter dose	Loading dose: ☐ 160mg injected day 1 — OR — ☐ 80mg injected each day 1 and day 2 followed by 80mg SC on day 15, then maintenance on day 29	1 starter kit -OR- QS for 1-month loading dose No Refills
Humira® (ADULT)	Maintenance: ☐ 40mg/0.4mL citrate free PEN ☐ 40mg/0.4mL citrate free PFS ☐ 40mg/0.8mL PEN	Maintenance dose: Inject 40mg subcutaneously every other week	☐ 1-month supply ☐ 3-month supply ☐ Refill QS 1 year unless otherwise noted ☐ Other _____

Humira and Biosimilars Order Form

Medication	Strength / Formulation	Directions	Quantity / Refills
	☐ 40mg/0.8mL PFS		
Humira® (adalimumab) — PEDIATRIC (weight _____ kg)			
Humira® (PEDIATRIC)	Starter: ☐ 40mg/0.4mL PFS for starter dose	Loading dose: ☐ 160mg injected day 1 — OR — ☐ 80mg injected each day 1 and day 2 followed by 80mg SC on day 15, then maintenance on day 29	1 starter kit -OR- QS for 1-month loading dose No Refills
Humira® (PEDIATRIC)	☐ 40mg/0.4mL PFS for starter dose	Loading dose: 80mg subcutaneously on day 1, then 40mg on day 15, then maintenance on day 29.	
Humira® (PEDIATRIC)	Maintenance: ☐ 40mg/0.4mL citrate free PEN ☐ 40mg/0.4mL citrate free PFS ☐ 40mg/0.8mL PEN ☐ 40mg/0.8mL PFS ☐ 80mg/0.8mL citrate free PEN ☐ 20mg/0.2mL PFS	Maintenance dose: ☐ Inject 40mg subcutaneously every other week ☐ Inject 20mg subcutaneously every other week	☐ 1-month supply ☐ 3-month supply ☐ Refill QS 1 year unless otherwise noted ☐ Other _____
Hyrimoz® (adalimumab-adaz) — Citrate Free — ADULT			
Hyrimoz® (ADULT)	80mg/0.8mL PEN Starter Pack (3 PENS)	Loading dose: ☐ Inject 160mg on day 1 — OR — ☐ Inject 80mg on day 1 and day 2 followed by 80mg SC on day 15, then maintenance on day 29	QS for 1-month loading dose No Refills
Hyrimoz® (ADULT)	☐ 40mg/0.4mL PEN ☐ 40mg/0.4mL PFS	Maintenance dose: Inject 40mg subcutaneously every other week	☐ 1-month supply ☐ 3-month supply ☐ Refill QS 1 year unless otherwise noted ☐ Other _____
adalimumab-adaz — Citrate Free — ADULT			
adalimumab-adaz (ADULT)	☐ 40mg/0.4mL PEN ☐ 40mg/0.4mL PFS ☐ 80mg/0.8mL PEN	Loading dose: ☐ Inject 160mg on day 1 — OR — ☐ Inject 80mg on day 1 and day 2 followed by 80mg SC on day 15, then maintenance on day 29	QS for 1-month loading dose No Refills
adalimumab-adaz (ADULT)	20mg/0.2mL PFS	Maintenance dose: Inject 40mg subcutaneously every other week	☐ 1-month supply

Humira and Biosimilars Order Form

Medication	Strength / Formulation	Directions	Quantity / Refills
			☐ 3-month supply ☐ Refill QS 1 year unless otherwise noted ☐ Other _____
Hyrimoz® (adalimumab-adaz) — Citrate Free — PEDIATRIC (weight _____ kg)			
Hyrimoz® (PEDIATRIC)	☐ 80mg/0.8mL and 40mg/0.4mL PFS Pediatric Crohn's Starter Pack (2 PFS) ☐ 80mg/0.8mL PFS Pediatric Crohn's Starter Pack (3 PFS)	Loading dose: For 17kg to <40kg: ☐ Inject 80mg SC on day 1, then 40mg on day 15, then maintenance on day 29 For ≥40kg: ☐ Inject 160mg on day 1 — OR — ☐ Inject 80mg each day 1 and day 2 followed by 80mg SC on day 15, then maintenance on day 29	QS for 1-month loading dose No Refills
Hyrimoz® (PEDIATRIC)	☐ 20mg/0.2mL PFS ☐ 40mg/0.4mL PFS ☐ 40mg/0.4mL PEN	Maintenance dose: For 17kg to <40kg: Inject 20mg SC every other week For ≥40kg: Inject 40mg SC every other week	☐ 1-month supply ☐ 3-month supply ☐ Refill QS 1 year unless otherwise noted ☐ Other _____
adalimumab-adaz — Citrate Free — PEDIATRIC (weight _____ kg)			
adalimumab-adaz (PEDIATRIC)	☐ 40mg/0.4mL PFS ☐ 40mg/0.4mL PEN ☐ 80mg/0.8mL PEN	Loading dose: For 17kg to <40kg: ☐ Inject 80mg SC on day 1, then 40mg on day 15, then maintenance on day 29 For ≥40kg: ☐ Inject 160mg on day 1 — OR — ☐ Inject 80mg each day 1 and day 2 followed by 80mg SC on day 15, then maintenance on day 29	QS for 1-month loading dose No Refills
adalimumab-adaz (PEDIATRIC)	20mg/0.2mL PFS	Maintenance dose: For 17kg to <40kg: Inject 20mg SC every other week For ≥40kg: Inject 40mg SC every other week	☐ 1-month supply ☐ 3-month supply ☐ Refill QS 1 year unless otherwise noted ☐ Other _____
Simlandi® (adalimumab-ryvk) — Citrate Free			
Simlandi®	☐ 40mg/0.4mL PFS ☐ 40mg/0.4mL PEN	Loading dose: ☐ Inject 160mg on day 1 — OR —	QS for 1-month loading dose No Refills

Humira and Biosimilars Order Form

Medication	Strength / Formulation	Directions	Quantity / Refills
		☐ Inject 80mg on day 1 and day 2 followed by 80mg SC on day 15, then maintenance on day 29	
Simlandi®	☐ 40mg/0.4mL PFS ☐ 40mg/0.4mL PEN	Maintenance dose: Inject 40mg subcutaneously every other week	☐ 1-month supply ☐ 3-month supply ☐ Refill QS 1 year unless otherwise noted ☐ Other _____
Other			

Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication.
 (S9359, S9379)

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN HERE	
----------------------	--

Date _____ ☐ Dispense as written Date _____ ☐ Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. All rights in the product names, trade names or logos of all third-party products that appear in this form, whether or not appearing with the trademark symbol, belong exclusively to their respective owners.